Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 6/20 | 0.97 |
| ▸ | DDX3X | O00571 | 6/20 | 0.55 |
| ▸ | CD74 | P04233 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15923549 | 1.00 | MIF (0.97) | MIFDDX3XCD74P2RX7CYP19A1 | |
| SCHEMBL18031109 | 0.98 | MIF (1.00) | MIFDDX3XCD74P2RX7CYP19A1 | |
| SCHEMBL16271203 | 0.85 | MIF (0.71) | MIFDDX3XCYP19A1 | |
| SCHEMBL15923943 | 0.85 | MIF (0.71) | MIFDDX3XP2RX7CYP19A1BCHE | |
| Bromide SCHEMBL1890839 | 0.84 | MIF (0.69) | MIFDDX3XCYP19A1 | |
| Bromide SCHEMBL1880796 | 0.84 | MIF (0.69) | MIFDDX3XCYP19A1 | |
| Bromide SCHEMBL1883955 | 0.84 | MIF (0.69) | MIFDDX3XCYP19A1 | |
| Bromide SCHEMBL1880908 | 0.84 | MIF (0.69) | MIFDDX3XCYP19A1 | |
| SCHEMBL13527245 | 0.83 | MIF (0.69) | MIFDDX3XP2RX7CYP19A1BCHE | |
| SCHEMBL1313081 | 0.83 | MIF (0.68) | MIFDDX3XCYP19A1BCHESPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244462-A1 | 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-08-25 | — | — | US | disclosed |
| US-20160244462-A1 | 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244462-A1 | 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF | XDH, DHFR, G6PD | MIF 1471/4885DDX3X 703/4885CD74 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.